reference standard comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-29. Numbers and descriptions here follow the published literature rather than marketing material.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
In fluid dynamics, the Hagen–Poiseuille equation, also known as the Hagen–Poiseuille law, Poiseuille law or Poiseuille equation, is a physical law that gives the pressure drop in an incompressible and Newtonian fluid in laminar flow flowing through a long cylindrical pipe of constant cross section. It can be successfully applied to air flow in the airways of the lungs, or the flow through a drinking straw or through a hypodermic needle. It was experimentally derived independently by Jean Léonard Marie Poiseuille in 1838 and Gotthilf Heinrich Ludwig Hagen, and published by Hagen in 1839 and then by Poiseuille in 1840–41 and 1846. The theoretical justification of the Poiseuille law was given by George Stokes in 1845. The assumptions of the equation are that the fluid is incompressible and Newtonian; the flow is laminar through a pipe of constant circular cross-section that is substantially longer than its diameter; and there is no acceleration of fluid in the pipe. For velocities and pipe diameters above a threshold, actual fluid flow is not laminar but turbulent, leading to larger pressure drops than calculated by the Hagen–Poiseuille equation. Poiseuille's equation describes the pressure drop due to the viscosity of the fluid; other types of pressure drops may still occur in a fluid (see a demonstration here).
=== Early career === Prismall grew up in Werribee, Victoria. He was drafted from the Western Jets Under 18s. He was Geelong's first pick in the 2004 draft, pick 32 overall, coincidentally this is the number he wore on his guernsey. The number 32 was made famous by Geelong player Garry Hocking. Prismall spent all of the 2005 season playing in the Victorian Football League (VFL) for Geelong's VFL team.
=== Neurology and cardiology === Theranostics extends beyond oncology and holds potential in the fields of neurology and cardiology. In neurology, theranostic approaches offer new avenues for the diagnosis and treatment of various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Advanced imaging techniques, including magnetic resonance imaging (MRI) and positron emission tomography (PET), allow for the visualization of neuroanatomy, functional connectivity, and molecular changes in the brain. This enables early detection, precise diagnosis, and monitoring of disease progression, facilitating the development of targeted therapeutic interventions. Similarly, in cardiology, theranostics play a significant role in the diagnosis and treatment of cardiovascular conditions. Non-invasive imaging modalities like MRI and computed tomography (CT) provide detailed information about cardiac structure, function, and blood flow, aiding in the assessment of heart disease and the guidance of interventions. Theranostic approaches in cardiology involve targeted drug delivery systems for the treatment of conditions such as atherosclerosis and restenosis, as well as image-guided interventions for precise stenting or catheter-based therapies.
==== Selected reaction monitoring ==== When employing selected reaction monitoring (SRM) or multiple reaction monitoring (MRM) modes, both Q1 and Q3 are set at a specific mass, allowing only a distinct fragment ion from a certain precursor ion to be detected. This method results in increased sensitivity. If Q1 and/or Q3 is set to more than a single mass, this configuration is called multiple reaction monitoring.
=== Economics === Tavaborole began phase III clinical trials in December 2010 and was approved by the US FDA in July 2014. Originally developed by Anacor, it is now marketed in the United States by Novartis subsidiary Sandoz. Anacor was paid US$65 million and also entered into a profit sharing scheme for future sales.
Sources: en.wikipedia.org
== Business model == Pilot is a vertical integration telehealth company that offers specific treatments for specific ailments. Patients complete an online assessment and pay a fee to Pilot to talk to a doctor. If treatment is recommended, the patient signs up for a monthly subscription. Medication is delivered to their specified address. Pilot acts as a wholesaler of Schedule 4 medications. Medications are supplied via partner pharmacies. In most cases, they do not offer items available through Medicare or the Pharmaceutical Benefits Scheme (PBS).
Chemical energy (or "chemical fuels") was an attractive option at the beginning, given the broad array of reversible chemical reactions (heavily based on acid-base chemistry) to switch molecules between different states. However, this comes with the issue of practically regulating the delivery of the chemical fuel and the removal of waste generated to maintain the efficiency of the machine as in biological systems. Though some AMMs have found ways to circumvent this, more recently waste-free reactions such based on electron transfers or isomerization have gained attention (such as redox-responsive viologens). Eventually, several different forms of energy (electric, magnetic, optical and so on) have become the primary energy sources used to power AMMs, even producing autonomous systems such as light-driven motors.
I Am Maximus ridden by Paul Townend wins the 2024 Grand National. Sunak condemns Iran's attack against Israel and says the UK is working to stabilise the situation. 14 April Sunak confirms that RAF fighter jets shot down "a number of drones" fired at Israel by Iran. Richard Lee, whose daughter Katrice Lee disappeared near a British military base in Paderborn, Germany, in 1981, says he will hand back his Army medals in protest at how the case was handled. Lawyers representing around 250 survivors of the Manchester Arena bombing confirm plans to take legal action against MI5. Charities supporting asylum seekers announce plans to launch legal challenges to moving people to Rwanda once legislation declaring it a safe country is passed in the coming days. The Duke of Kent confirms he is stepping down as Colonel of the Scots Guards after 50 years, and handing the role over to the Duke of Edinburgh. The UK experiences its warmest temperature of 2024 so far, with 21.8 °C recorded in the village of Writtle, near Chelmsford, Essex. 15 April Sunak urges "all sides" to "show restraint" after Iran's attack on Israel. A report by the Resolution Foundation calls for changes to Universal Credit to take into account an aging population with health problems. 16 April Figures show the rate of UK unemployment rose to 4.2% between December 2023 and March 2024, its highest level for six months. EasyJet cancels all flights to and from Tel Aviv for the whole of the summer, citing safety concerns following Iran's drone and missile attack on Israel.
== Ecology == The diet of the arapaima consists of fish, crustaceans, fruits, seeds, insects, and small land animals that walk near the shore (such as mammals and birds). The fish is an air breather, using its labyrinth organ, which is rich in blood vessels and opens into the fish's mouth, an advantage in oxygen-deprived water that is often found in the Amazon River. This fish is able to survive in oxbow lakes with dissolved oxygen as low as 0.5 ppm. In the wetlands of the Araguaia, one of the most important refuges for this species, it is the top predator in such lakes during the low-water season, when the lakes are isolated from the rivers and oxygen levels drop, rendering its prey lethargic and vulnerable. Arapaima may leap out of the water if they feel constrained by their environment or harassed.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.